EarliTec Diagnostics, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) authorization of the second generation of its EarliPoint™ Evaluation for
First FDA-cleared tool to assist clinicians in diagnosing and assessing autism in children as young as 16 months old ATLANTA – June
EarliTec Diagnostics Announces $19.5 Million Financing to Advance Autism Diagnosis and Treatment in Children as Young as 16 Months of Age The
Using clinically validated measures, we are creating novel technologies that enable parents and providers to know where an individual child is on the spectrum and to tailor treatment for the greatest personal gains.
Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.
Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.
Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.